Literature DB >> 23264888

Optimal Immunofluorescent Staining for Human Factor IX and Infiltrating T Cells following Gene Therapy for Hemophilia B.

Geoffrey L Rogers1, Brad E Hoffman.   

Abstract

Immunofluorescent imaging is a valuable tool for investigating the outcome of gene therapy within the transduced tissue. With a multi-labeling technique, it is possible to both characterize local expression of the transgene and to evaluate the severity of the adaptive immune response through cytotoxic T cell infiltration. It is critical that the experimental parameters are optimal in order to prevent misinterpretation of important pathological events. To optimize this staining protocol, murine liver and skeletal muscle was transduced using recombinant adeno-associated virus encoding human factor IX. After testing several common cryo-preservative and fixative techniques, we found that optimal tissue integrity and antigen (factor IX and CD8) detection was achieved by freezing muscle tissue on liquid nitrogen-cooled isopentane (also called methylbutane or 2-methylbutane), followed by fixation with acetone at room temperature. The staining protocol described herein requires only about two hours, yet maintains exquisite specificity even at high magnification under confocal microscopy.

Entities:  

Year:  2012        PMID: 23264888      PMCID: PMC3526188          DOI: 10.4172/2157-7412.s1-012

Source DB:  PubMed          Journal:  J Genet Syndr Gene Ther        ISSN: 2157-7412


  17 in total

1.  Comparison of formalin-free tissue fixatives: a proteomic study testing their application for routine pathology and research.

Authors:  Hannelore Kothmaier; Daniela Rohrer; Elvira Stacher; Franz Quehenberger; Karl-Friedrich Becker; Helmut H Popper
Journal:  Arch Pathol Lab Med       Date:  2011-06       Impact factor: 5.534

2.  Optimized production of high-titer recombinant adeno-associated virus in roller bottles.

Authors:  Y L Liu; K Wagner; N Robinson; D Sabatino; P Margaritis; W Xiao; R W Herzog
Journal:  Biotechniques       Date:  2003-01       Impact factor: 1.993

3.  Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer.

Authors:  Ou Cao; Eric Dobrzynski; Lixin Wang; Sushrusha Nayak; Bethany Mingle; Cox Terhorst; Roland W Herzog
Journal:  Blood       Date:  2007-04-16       Impact factor: 22.113

4.  Muscle as a target for supplementary factor IX gene transfer.

Authors:  Brad E Hoffman; Eric Dobrzynski; Lixin Wang; Lauren Hirao; Federico Mingozzi; Ou Cao; Roland W Herzog
Journal:  Hum Gene Ther       Date:  2007-07       Impact factor: 5.695

Review 5.  Overview of cell fixation and permeabilization.

Authors:  M A Melan
Journal:  Methods Mol Biol       Date:  1994

Review 6.  Recommendations for the biopsy procedure and assessment of skeletal muscle biopsies.

Authors:  J R Anderson
Journal:  Virchows Arch       Date:  1997-10       Impact factor: 4.064

7.  Evaluation of the value of frozen tissue section used as "gold standard" for immunohistochemistry.

Authors:  Shan-Rong Shi; Cheng Liu; Llana Pootrakul; Laurie Tang; Andrew Young; Ryan Chen; Richard J Cote; Clive R Taylor
Journal:  Am J Clin Pathol       Date:  2008-03       Impact factor: 2.493

8.  Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer.

Authors:  Federico Mingozzi; Yi-Lin Liu; Eric Dobrzynski; Antje Kaufhold; Jian Hua Liu; YuQin Wang; Valder R Arruda; Katherine A High; Roland W Herzog
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

9.  AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.

Authors:  Catherine S Manno; Amy J Chew; Sylvia Hutchison; Peter J Larson; Roland W Herzog; Valder R Arruda; Shing Jen Tai; Margaret V Ragni; Arthur Thompson; Margareth Ozelo; Linda B Couto; Debra G B Leonard; Frederick A Johnson; Alan McClelland; Ciaran Scallan; Erik Skarsgard; Alan W Flake; Mark A Kay; Katherine A High; Bertil Glader
Journal:  Blood       Date:  2002-12-19       Impact factor: 22.113

10.  Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response.

Authors:  Catherine S Manno; Glenn F Pierce; Valder R Arruda; Bertil Glader; Margaret Ragni; John J Rasko; John Rasko; Margareth C Ozelo; Keith Hoots; Philip Blatt; Barbara Konkle; Michael Dake; Robin Kaye; Mahmood Razavi; Albert Zajko; James Zehnder; Pradip K Rustagi; Hiroyuki Nakai; Amy Chew; Debra Leonard; J Fraser Wright; Ruth R Lessard; Jürg M Sommer; Michael Tigges; Denise Sabatino; Alvin Luk; Haiyan Jiang; Federico Mingozzi; Linda Couto; Hildegund C Ertl; Katherine A High; Mark A Kay
Journal:  Nat Med       Date:  2006-02-12       Impact factor: 53.440

View more
  8 in total

1.  The Balance between CD8+ T Cell-Mediated Clearance of AAV-Encoded Antigen in the Liver and Tolerance Is Dependent on the Vector Dose.

Authors:  Sandeep R P Kumar; Brad E Hoffman; Cox Terhorst; Ype P de Jong; Roland W Herzog
Journal:  Mol Ther       Date:  2017-03-09       Impact factor: 11.454

2.  Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid.

Authors:  Koen Vercauteren; Brad E Hoffman; Irene Zolotukhin; Geoffrey D Keeler; Jing W Xiao; Etiena Basner-Tschakarjan; Katherine A High; Hildegund Cj Ertl; Charles M Rice; Arun Srivastava; Ype P de Jong; Roland W Herzog
Journal:  Mol Ther       Date:  2016-03-29       Impact factor: 11.454

3.  Improved Adeno-associated Viral Gene Transfer to Murine Glioma.

Authors:  I Zolotukhin; D Luo; Os Gorbatyuk; Be Hoffman; Kh Warrington; Rw Herzog; Jk Harrison; O Cao
Journal:  J Genet Syndr Gene Ther       Date:  2013-04-29

4.  Regulatory T cells and TLR9 activation shape antibody formation to a secreted transgene product in AAV muscle gene transfer.

Authors:  Roland W Herzog; Mario Cooper; George Q Perrin; Moanaro Biswas; Ashley T Martino; Laurence Morel; Cox Terhorst; Brad E Hoffman
Journal:  Cell Immunol       Date:  2017-08-01       Impact factor: 4.868

5.  Promoterless gene targeting without nucleases ameliorates haemophilia B in mice.

Authors:  A Barzel; N K Paulk; Y Shi; Y Huang; K Chu; F Zhang; P N Valdmanis; L P Spector; M H Porteus; K M Gaensler; M A Kay
Journal:  Nature       Date:  2014-10-29       Impact factor: 49.962

6.  Neonatal Gene Therapy for Hemophilia B by a Novel Adenovirus Vector Showing Reduced Leaky Expression of Viral Genes.

Authors:  Shunsuke Iizuka; Fuminori Sakurai; Masashi Tachibana; Kazuo Ohashi; Hiroyuki Mizuguchi
Journal:  Mol Ther Methods Clin Dev       Date:  2017-07-08       Impact factor: 6.698

7.  Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B.

Authors:  Geoffrey L Rogers; Ashley T Martino; Irene Zolotukhin; Hildegund C J Ertl; Roland W Herzog
Journal:  J Transl Med       Date:  2014-01-25       Impact factor: 5.531

8.  Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy.

Authors:  Thais B Bertolini; Jamie L Shirley; Irene Zolotukhin; Xin Li; Tsuneyasu Kaisho; Weidong Xiao; Sandeep R P Kumar; Roland W Herzog
Journal:  Front Immunol       Date:  2021-05-31       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.